Press Releases

An overview of how combining genomics, transcriptomics, proteomics, and other omics layers gives a fuller picture of disease biology. The piece outlines where multiomics is already reshaping research and clinical practice.

A look at where AI is already improving cancer diagnosis and treatment planning, and where the technology still falls short. The piece weighs near-term clinical impact against longer-term possibilities.

Signios Bio and Illumina launch a grant program built around the industry’s largest NGS-based proteomics panel. The award gives recipients expanded discovery power for biomarker research.

Signios Bio officially launches, pairing AI-driven bioinformatics with an advanced multiomics platform. The company positions itself to accelerate precision medicine and drug discovery programs.

MedGenome names Felix Olale, M.D., Ph.D. as CEO and Jennifer Rose as Chief Commercial Officer. The leadership additions are aimed at driving the company’s U.S. expansion.

MedGenome becomes the first commercial provider in the Bay Area to bring the PacBio Revio platform fully in-house. The move expands full-service long-read sequencing capacity for clients.

MedGenome reveals the winning projects for its 2024 de novo genome assembly and annotation grant. Winners gain access to reference-quality genome assembly support.

MedGenome appoints Martin Dewhurst to chair its Advisory Board. The appointment brings added strategic and industry guidance to the company’s leadership.

MedGenome and PacBio launch a grant supporting de novo genome assembly and annotation for non-model organisms. The program targets researchers working outside well-characterized reference genomes.

MedGenome earns 10x Genomics Certified Service Provider status for single-cell sequencing. The qualification recognizes the lab’s proficiency across single-cell workflows.